These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 34030727)

  • 1. Oligomerization of Lrrk controls actin severing and α-synuclein neurotoxicity in vivo.
    Sarkar S; Bardai F; Olsen AL; Lohr KM; Zhang YY; Feany MB
    Mol Neurodegener; 2021 May; 16(1):33. PubMed ID: 34030727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lrrk promotes tau neurotoxicity through dysregulation of actin and mitochondrial dynamics.
    Bardai FH; Ordonez DG; Bailey RM; Hamm M; Lewis J; Feany MB
    PLoS Biol; 2018 Dec; 16(12):e2006265. PubMed ID: 30571694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
    Henderson MX; Peng C; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synphilin-1 attenuates mutant LRRK2-induced neurodegeneration in Parkinson's disease models.
    Liu J; Li T; Thomas JM; Pei Z; Jiang H; Engelender S; Ross CA; Smith WW
    Hum Mol Genet; 2016 Feb; 25(4):672-80. PubMed ID: 26744328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease risk genes act in glia to control neuronal α-synuclein toxicity.
    Olsen AL; Feany MB
    Neurobiol Dis; 2021 Nov; 159():105482. PubMed ID: 34390834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.
    Lin X; Parisiadou L; Gu XL; Wang L; Shim H; Sun L; Xie C; Long CX; Yang WJ; Ding J; Chen ZZ; Gallant PE; Tao-Cheng JH; Rudow G; Troncoso JC; Liu Z; Li Z; Cai H
    Neuron; 2009 Dec; 64(6):807-27. PubMed ID: 20064389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
    Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
    Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of LRRK2 kinase activity promotes anterograde axonal transport and presynaptic targeting of α-synuclein.
    Brzozowski CF; Hijaz BA; Singh V; Gcwensa NZ; Kelly K; Boyden ES; West AB; Sarkar D; Volpicelli-Daley LA
    Acta Neuropathol Commun; 2021 Nov; 9(1):180. PubMed ID: 34749824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.
    Albanese F; Mercatelli D; Finetti L; Lamonaca G; Pizzi S; Shimshek DR; Bernacchia G; Morari M
    Neurobiol Dis; 2021 Nov; 159():105487. PubMed ID: 34419621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice.
    Henderson MX; Sengupta M; McGeary I; Zhang B; Olufemi MF; Brown H; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2019 Feb; 7(1):28. PubMed ID: 30808409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.
    Schapansky J; Khasnavis S; DeAndrade MP; Nardozzi JD; Falkson SR; Boyd JD; Sanderson JB; Bartels T; Melrose HL; LaVoie MJ
    Neurobiol Dis; 2018 Mar; 111():26-35. PubMed ID: 29246723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease.
    Cresto N; Gardier C; Gubinelli F; Gaillard MC; Liot G; West AB; Brouillet E
    Eur J Neurosci; 2019 Feb; 49(3):339-363. PubMed ID: 30269383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory- and oxidative stress-related pathways upon treatment with α-synuclein fibrils.
    Russo I; Kaganovich A; Ding J; Landeck N; Mamais A; Varanita T; Biosa A; Tessari I; Bubacco L; Greggio E; Cookson MR
    Neurobiol Dis; 2019 Sep; 129():67-78. PubMed ID: 31102768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
    Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N
    Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motor Impairments and Dopaminergic Defects Caused by Loss of Leucine-Rich Repeat Kinase Function in Mice.
    Huang G; Bloodgood DW; Kang J; Shahapal A; Chen P; Kaganovsky K; Kim JI; Ding JB; Shen J
    J Neurosci; 2022 Jun; 42(23):4755-4765. PubMed ID: 35534227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRRK2 Ablation Attenuates Αlpha-Synuclein-Induced Neuroinflammation Without Affecting Neurodegeneration or Neuropathology In Vivo.
    Van der Perren A; Cabezudo D; Gelders G; Peralta Ramos JM; Van den Haute C; Baekelandt V; Lobbestael E
    Neurotherapeutics; 2021 Apr; 18(2):949-961. PubMed ID: 33594532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's Disease-Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance.
    Streubel-Gallasch L; Giusti V; Sandre M; Tessari I; Plotegher N; Giusto E; Masato A; Iovino L; Battisti I; Arrigoni G; Shimshek D; Greggio E; Tremblay ME; Bubacco L; Erlandsson A; Civiero L
    Mol Neurobiol; 2021 Jul; 58(7):3119-3140. PubMed ID: 33629273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
    Daher JP
    Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors.
    Pajarillo E; Rizor A; Lee J; Aschner M; Lee E
    Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):1992-2000. PubMed ID: 30481588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons.
    López de Maturana R; Lang V; Zubiarrain A; Sousa A; Vázquez N; Gorostidi A; Águila J; López de Munain A; Rodríguez M; Sánchez-Pernaute R
    J Neuroinflammation; 2016 Nov; 13(1):295. PubMed ID: 27863501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.